Skip to main content
. Author manuscript; available in PMC: 2016 Sep 13.
Published in final edited form as: Mol Cancer Res. 2016 Feb 5;14(4):363–373. doi: 10.1158/1541-7786.MCR-15-0399

Figure 2. miR-155 over-expression in vivo leads to an increase in mutation frequency.

Figure 2

miR-155 over-expression was confirmed by qRT-PCR in the (A) spleen and (B) brain. (C) Representative images of spleens from WT and 155KI animals prior to DNA isolation. (D) Mutation frequency is measured by supFG1 mutation reporter gene in the presence or absence of miR-155 over-expression in the spleen or in lymphadenopathy tissue (lymphoma), or (E) brain at 8 weeks of age. In both D and E, error bars are calculated based on standard error of the mean and p-value is calculated by unpaired t-test (WT spleen: n=3; 155KI spleen: n=4; 155KI tumor: n=2; WT brain: n=4; 155KI brain: n=3).